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Abstract
Background: In vitro maturation (IVM) of immature oocytes retrieved from ovarian
tissue has been considered as a valuable approach for fertility preservation in
cancerous patients.
Objective: To evaluate the efficacy of vitrification on oocyte maturation, survival rates,
as well as the subcellular oocyte quality post IVM.
Materials and Methods: The ovarian cortexes from 19 women with cervix and uterine
malignancy aged 21–39 yr were collected. Cumulus-oocyte complexes were aspirated
from all visible antral follicles. 102 immature oocytes were collected, and 43 oocytes
were detected appropriately for IVM (control group). Also, 59 immature oocytes were
vitrified, then matured in vitro (IVM) in two groups: with Growth/differentiation factor
9 (GDF9) (group 1) and without GDF9 (group 2) supplementation. Rates of oocytes
viability, maturation, and survival along with meiotic spindle visualization and zona
pellucida birefringence were assessed with Polyscope.
Results: The rate of maturation was significantly higher in controls (55.8%) compared
to the other groups. Maturation rate was 23.3% in oocytes cultured in IVM medium
enriched with GDF9, and 27.6% in those cultured in IVM medium lacking GDF9 (p
= 0.86). Also, the meiotic spindle was present in 74.4% of control oocytes which
was significantly higher than the other groups. The proportion of high zona pellucida
birefringence was higher in the controls when compared with group 1 (51.2% vs. 23.3%,
respectively, p = 0.04).
Conclusion: Vitrification had a detrimental effect on oocyte maturation, viability as well
as the subcellular quality of the oocytes after IVM in cancerous women.
Key words: IVM, Vitrification, Fertility preservation, Maturation rate, Meiotic spindle,
Zona pellucida birefringence.
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1. Introduction
Since the diagnosis and treatment of cancer-
ous patients have been developed successfully in
recent years, fertility preservation has been speci-
fied as a priority for these patients (1). In this way,
fertility preservation could be beneficial for several
groups including men, women, and children with
malignant diseases undergoing gonadotoxic treat-
ment, patients affected by other non-oncologic
malignancies, and age-related infertility (2). It is
well-documented that chemo- and radiotherapy
can result in loss of reproductive function and
decline ovarian reservation in these patients (3).
The methods have been already proposed to over-
come the induced infertility consisting the phar-
macological protection, ovarian transposition or
transplantation, oophorectomy, as well as oocytes,
embryos, and ovarian tissue cryopreservation (4,
5). Oocytes could be retrieved at the metaphase
II (MII), metaphase I (MI), or germinal vesicle (GV)
stage from the ovarian tissues (OTs). The retrieved
immature oocytes may be cryopreserved in this
step, and then subjected to the in vitro matura-
tion (IVM) procedure. IVM was described as the
maturation of immature oocytes in the culture
media, with the specific advantages of low cost
with minor side effects for the immature oocytes
(6). It has been reported that vitrification of GV
oocytes followed by IVM is an effective method
for fertility preservation in the patients who did
not involve ovulation stimulation and for cancerous
cases who cannot postpone their chemotherapy
program (7). Even though pregnancies and live
births after human oocyte cryopreservation have
been reported (8), there are still disagreements
about IVM procedure with regards to the mat-
uration stage of vitrified oocytes and its effect
on oocytes fertility competence. Likewise, there
are controversies with regard to the relationship
between zona pellucida (ZP) birefringence as well
as meiotic spindle (MS) detection and the rates of
oocyte maturation and fertilization after IVM (9–11).
On the other hand, GDF9 (growth differentiation
factor 9) plays a key role in the growth of granulosa
cells, and oocyte differentiation. In addition, the
high level of GDF9 in human follicular fluid resulted
in oocyte nuclear maturation (12).
The aim of this study was to evaluate the efficacy
of vitrification on the survival, maturation, and
viability rates of immature oocytes post IVM that
were isolated from the cortex of OTs in cancerous
patients.
2. Materials and Methods
In this experimental study, 32 women who were
referred to the Department of Gynecology, Shahid
Sadoughi Hospital, Shahid Sadoughi University of
Medical Sciences, Yazd, Iran, were recruited. Our
inclusion was women aged 15–45 yr with the cervix
and uterine malignancy that were seeking fertility
preservation. Women with bilateral ovarian cancer
were excluded from the study. An ovarian biopsy
or OT resection was performed during therapeutic
surgery by laparotomy or laparoscopy. Due to the
required urgent surgery, the day of the patients’
menstrual cycle was not considered.
Thirteen women were lacking oocytes in the
aspirated follicular fluid and excluded from the
study. OTs were transported from the hospital to
the IVF laboratory in Ham’s F10+HSA medium at
4∘C on ice within 15–20 min. At arrival, cumulus-
oocyte complexes (COCs) were immediately aspi-
rated from all visible antral follicles using 19-gauge
syringe needles. The aspirated follicular fluid was
shed directly into a Petri dish and examined for
COCs under a stereomicroscope (37∘C). Oocytes
which were not denuded during aspiration were
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mechanically or chemically denuded with expo-
sure to 80 IU/ml hyaluronidase solution (Sigma
Aldrich, UK) before vitrification. It should be noted
that all of the collected oocytes were immature
at MI (4 oocytes) or GV (98 oocytes) stages.
Oocytes were divided into three groups: Group
1; oocytes which were cultured in IVM medium
supplemented GDF9 (Sigma-Aldrich, Copenhagen,
Denmark) after vitrification. Group 2; oocytes which
were cultured in IVM medium without GDF9 after
vitrification. Group 3 (Control); fresh oocytes which
were cultured in IVM medium free of GDF9.
2.1. Vitrification
The immature oocytes were vitrified using
RapidVitTM Oocyte kit (Vitrolife Co, Sweden) fol-
lowing the manufacturer’s instructions; To do this,
we placed 1cc from each of the culture mediums,
“Vitri 1TM Oocyte and Vitri 2TM Oocyte”, in the wells
of a multi-well plate, separately and then warmed
to 37∘C in environment. First, the oocytes were
transferred into “Vitri 1TM Oocyte”. The oocytes
remained in the solution for at least 5 min, and
a maximum of 20 min. Then, the oocytes were
moved into “Vitri 2TM Oocyte” for 2–5 min. The
oocytes usually tended to float to the surface. If
so, they were collected and placed to the bottom
of the dish. Within 5 minutes, it was expected that
the oocytes be re-expand to their original volume.
It would indicate that the medium temperature is
not at 37 ∘C, if re-expansion took more than this
time (5 min). After full oocyte re-expansion, we
made a 20μl drop of “Vitri 3 TM Oocyte” into a
culture dish for an easier loading on cryodevice.
After 15 seconds of oocytes transfer to the 20μl
“Vitri 3 TM Oocyte” droplet, they were collected and
placed in the cryodevice, then immersed into liquid
nitrogen.
2.2. Warming and in vitro maturation
Warming the vitrified oocytes was performed
by RapidWarmTM Oocyte kit, (Vitrolife Co., Swe-
den) following the manufacturer’s instructions. For
warming, the cryodevice was removed from the
liquid nitrogen and dipped into Warming Solution
1 (Warm 1TM Oocyte), for 1 min and moved into
a Warm 2TM for 3 min. Then, the oocytes were
moved into a Warm 3TM for 5 min. Finally, the
oocytes were transferred into Warm 4TM for 5–10
min.Medium volume for each stepwas 1ml in 4-well
dishes at 37∘C. Two separate dishes containing
IVM medium were prepared by a technician who
was blinded to the study. GDF9 (200 ng/ml) was
added to one of the IVMmedia (13). Sibling oocytes
were transferred into two media: IVM medium with
GDF9 (group 1) and IVM medium without GDF9
(group 2). The control group included the fresh
immature oocytes assigned for IVM. The immature
oocytes in three groups were incubated (at 37∘C
with 5% CO2 and 95% air, with high humidity) in
IVM Medium (MediCult IVM® System, Pr, Origio
company, Denmark) supplemented with 75 mIU/ml
FSH, 100 mIU/ml hCG, and 20% human serum
albumin (HSA) added to vial two of the media. The
oocytes were then evaluated for maturity between
24 and 48 h after IVM. Oocyte maturation was
assessed by the presence of the first polar body
under a stereomicroscope (Nikon, Japan). Oocytes
were considered morphologically survived after
warming by the presence of a round shape and
size along with the intact ZP, and clear perivitelline
space, with no sign of degeneration.
2.3. Meiotic spindle and ZP birefrin-
gence evaluation
Meiotic spindle and ZP birefringence were
examined using PolScope as described previously
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(14). After placing the mature oocytes, individually,
in an well-equilibrated 3-µl droplet of buffered
medium (G-Mops-V1; Vitrolife), in a glass-bottomed
culture dish (WillCo-Dish; Bellco Glass, USA), the
presence of MS and homogeny of the inner layer
of the ZP were evaluated using a polarizing opti-
cal system (OCTAX PolarAIDE; Octax, Germany).
According to the results determined by the soft-
ware of the PolarAid system, the oocytes were
stratified into two classifications of presence or
absence of MS. Also, three categories of high
ZP (green), moderate ZP (yellow) and low ZP
birefringence (red) were assigned (15) (Figure 1).
2.4. Assessment of viability
Oocytes viability assessment was performed
with Hoechst/propidium iodide (H/PI) nuclear stain-
ing based on a previous report (16). Briefly, the
oocytes were washed twice in prewarmed Ca+2
and Mg +2 free phosphate buffer saline (PBS-).
Then, they were incubated in 20 µg/ml of H33342
(Sigma, USA) and 20 µg/ml of PI (Sigma, USA) for
15 min. After that, the oocytes were washed thrice
in warm PBS until the residual dye was resolved.
The cells were examined under a fluorescence
microscope (Olympus; Japan). The fluorescent dye
enters both alive and dead cells, while PI just
enters the cells with altered membrane integrity.
Therefore, alive cells with intact cell membrane
showed blue fluorescence (PI-negative) and cells
with late apoptosis and necrosis appeared as red
(PI-positive) (Figure 2).
2.5. Outcome measurements
The primary outcome was the oocyte maturation
rate. Oocyte maturation was assessed by the
presence of the first polar body under a dissecting
microscope. Oocyte survival rate and viability were
assessed as secondary outcomes. Survival of the
oocyte was defined as regular oocyte shape and
diameter, observing intact ZP and oolemma, a
clear perivitelline space and no sign of ooplasmic
degeneration. For oocyte viability, the dead and
the viable cells were identified according to the PI
status. The correlation between women age and
the number of recovered oocytes was calculated.
2.6. Ethical consideration
The patients voluntarily participated in the study
and signed the written informed consent before
the procedure. The study was reviewed and
approved by the Ethics Committee of Shahid
Sadoughi University of Medical Sciences, Yazd,
Iran (IR.SSU.RSI.REC.1395.1).
2.7. Statistical analysis
Statistical analysis was performed using the
Statistical Package for the Social Science version
20.0 (SPSS Inc, Chicago. IL, USA). The data were
analyzed using the Chi-square test. A Pearson rank
correlation was used to analyze the relationships
between age and the number of oocytes. P-value
of < 0.05 was considered significant.
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Figure 1: Meiotic spindle (MS) and ZP birefringence evaluation. A: Meiotic spindle in the mature oocyte. B, C, and D: ZP
birefringence (B: Green; C: Yellow; D: Red) (40× magnification).
Figure 2: Viable staining of the oocytes. A: live oocyte with intact cell membrane was shown blue fluorescence (PI-negative). B:
live oocyte with intact cell membrane C: Dead cell (PI-positive) (20× magnification).
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3. Results
Totally, 102 immature oocytes were obtained
with the mean of 5.37 ± 3.14 oocytes per patient.
The mean age of women was 31.74 ± 5.06. The
women age negatively impacted the number of
oocytes obtained from the ovarian samples. How-
ever, there was no significant statistical correlation
between the age and the number of recovered
oocytes (rs = –0.34; p = 0.15). The percentage of
mature oocytes was significantly higher in the con-
trol group (55.8%) compared to the other groups
undergoing IVM after vitrification. Maturation rate
was 23.3% in oocytes cultured in IVM medium
enriched with GDF9 and 27.6% in those cultured
in IVM medium lacking GDF9 (p = 0.86). Also,
the rates of arrested and degenerated oocytes
were lower in controls than other groups (Table
I). The data showed that survival rate in addition
to the viability of oocytes after vitrification was
comparable between groups 1 and 2 (Table I).
The findings indicated that MS visualization was
present in 74.4% of the oocytes in controls which
was significantly higher than the other groups.
Nevertheless, the percentage of visualized MS was
similar between groups 1 and 2 (Table II). The
proportion of high ZP birefringence was higher in
the control group compared with the IVM group
plus GDF9 (51.2% vs. 23.3% respectively, p =
0.04). In addition, the lower rate of moderate ZP
birefringence attained in the control group (25.4%).
But the difference did not reach a significant level
in comparison with the other groups. Low ZP
birefringence was comparable among the three
groups (Table II).
Table I: Maturation rate, survival rate, and viability of oocytes in three groups.
Variable Group 1 (With
GDF9) (n = 30)
Group 2 (Without
GDF9) (n = 29)
Group 3 (Control
Group) (n = 43)
P-value
Maturation rate
Mature 7 (23.3) 8 (27.6) 24 (55.8) 0.02𝑎
Arrest 14 (46.7) 14 (48.3) 12 (27.9) 0.04𝑏
Degeneration 9 (30) 7 (24.1) 7 (16.3) 0.86𝑐
Survival rate 21 (70) 20 (69) – 0.93𝑐
Viability
Alive 22 (73.3) 21 (72.4) – 0.93𝑐
Dead 8 (26.7) 8 (27.6)
Note: Data are presented as number (%); Differences between groups using Chi-squared test; a: group 1
vs. group 3; b: group 2 vs. group 3; c: group 1 vs. group 2; GDF9: Growth differentiation factor-9
Table II: Meiotic spindle visualization and Zona pellucida birefringence among three groups.
Variable Group 1 (With
GDF9) (n = 30)
Group 2 (Without
GDF9) (n = 29)
Group 3 (Control
Group) (n = 43)
P-value
Meiotic spindle 0.03𝑎
Visible 2 (6.7) 2 (6.9) 11 (25.5) 0.04𝑏
Invisible 28 (93.3) 27 (93.1) 32 (74.4) 0.97𝑐
Zona pellucida
Green 7 (23.3) 7 (24.1) 22 (51.2) 0.04𝑎
Yellow 14 (46.7) 14 (48.3) 11 (25.6) 0.05𝑏
Red 9 (30) 8 (27.6) 10 (23.3) 0.97𝑐
Note: Data are presented as number (%); Differences between groups using Chi-squared test; a: group 1
vs. group 3; b: group 2 vs. group 3; c: group 1 vs. group 2; GDF9: Growth differentiation factor-9
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4. Discussion
In spite of significant improvements in IVM
technique and progress in pregnancy and implan-
tation rates with in vitro matured oocytes, the
need for more objective and accurate investiga-
tion has been encouraged. For the first time, we
evaluated the post-thawing outcomes of vitrified
immature oocytes collected from the excised ovar-
ian tissue. Our study showed that vitrification of
immature oocytes before IVM has a detrimental
effect on maturation rate during IVM program.
We found no significant correlation between age
and the number of recovered oocytes. Simi-
larly, another study reported no significant cor-
relation between the number of the collected
oocytes from the ovarian medulla tissue and
the patients’ age (17). Whereas Fasano and col-
leagues showed a significant negative correlation
between the number of retrieved oocytes and
female age. They collected a significantly higher
number of oocytes from the OT of the pre-
pubertal girls compared with adults (18). Other
studies implemented in infertile patients about the
age of 30 yr have stated that 6–20 retrieved
oocytes during ovarian stimulation may improve
the live-birth rate (19, 20). However, these results
are reported from controlled ovarian stimulation
cycle, and could not generalize to IVM set-
ting.
As the main outcome, the maturation rate was
significantly higher in the oocytes that did not
vitrified compared with vitrified oocytes. Several
reports indicated that oocyte maturation rate was
significantly higher for oocytes matured before
vitrification than those vitrified before IVM (6, 16).
In addition, our recent review and meta-analysis
revealed that oocyte vitrification decreases the
maturation rate significantly but survival and fer-
tilization rates along with cleavage rat did not
significantly vary between the oocytes vitrified
before and after IVM (21). In addition, we found
similar results in our previous report; also, the
maturation rate in women under the age of 30
was higher than older patients in both fresh and
vitrified IVM (22). In this way, Yin and colleagues
vitrified MII oocytes after IVM and found that
maturation rate in patients below 20 years was
significantly higher than patients aged under or
above 30 yr (17). In general, previous studies
demonstrated that cryopreservation procedure has
a negative effect on oocyte maturation capacity
(23), particularly when the oocytes were vitrified in
immature GV stage and then subjected to IVM (24).
It is documented that some disorders may occur
during the vitrification process in different cellular
components, such as cytoskeleton abnormalities
as well as chromosome separation instabilities
and calcium signaling system disturbances (25).
It is also shown that vitrified MI oocytes are
more capable to reach MII stage after warming
when compared to vitrified GV oocytes. It may
be due to the first step of maturation which is
more vital and mainly affected by vitrification (26).
A good option in this subject may define as
embryo formation after IVM followed by embryo
vitrification. Our previous study showed that the
immature oocytes retrieved from the ovarian tissue
of cancer women could successfully subject to IVM
for the generation of good quality and freezable
embryos using intracytoplasmic sperm injection
(ICSI) (27).
Moreover, we evaluated the effect of GDF9
supplementation on oocyte maturation. Interest-
ingly, we observed that oocyte maturation rate
was comparable between two groups of frozen-
thawed oocytes which treated or not treat with
GDF9. But, significantly higher maturation rate was
detected in the control group compared to the
two aforementioned groups. It is well documented
that GDF9 is involved in the folliculogenesis, also
in the final stages of maturation, as mutations
or deletion of GDF9 gene is associated with
fertility problem and reproductive defects in rats,
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mice, sheep, and humans (28). Our results may
demonstrate that vitrification play a more impor-
tant role in oocyte maturation in comparison with
GDF9 supplementation. Conversely, other studies
reported the improvement of ovarian follicle growth
and differentiation (29) along with subsequent
embryo development in mice (13). Likewise, the
relationship between the levels of GDF9 and
nuclear oocyte maturation has been shown in
human (12). Similarly, Hreinsson and colleagues
showed that GDF9 enhanced the growth, devel-
opment, and survival of human ovarian follicles
(30).
In addition, we evaluated the oocyte survival
rate after vitrification which was similar to group
1 (70%) and 2 (69%). The results showed that
the vitrification procedure had no negative effect
on the survival rate regardless of GDF9 supple-
mentation. Likewise, two other studies reported
oocyte survival rate of 64% (17) and 61.5% (31)
after vitrification of GV and MII oocytes, respec-
tively. It is also indicated previously that sur-
vival rate after warming is comparable between
oocytes that vitrified in GV and MII stages (24).
Similarly, animal studies reported high survival
rates after oocyte vitrification and concluded that
oocyte vitrification is a very effective method for
cryopreservation of mouse and rat oocytes (32,
33). It is well known that during the vitrification
process, the oocytes are exposed to high cool-
ing rates along with high cryoprotectant concen-
trations for preventing ice-crystal formation and
increasing the oocyte survival rate (34, 35). We
also assessed the viability of oocytes in the pres-
ence or absence of GDF9. The results showed
the similar viability rates between the oocytes
in two groups. Recently, Yazdanpanah and co-
workers compared post-IVM viability rate between
53 immature oocytes in fresh and 50 immature
oocytes in the vitrification group. They stated a
significantly reduced viability rate in vitrified IVM
group (16).
In the present study, ZP birefringence and
MS visualization were assessed as oocyte quality
markers after vitrification and IVM. The percent-
ages of high ZP birefringence and visualized MS
were significantly higher in the oocytes without
vitrification in comparison with vitrified oocytes
with or without GDF9 treatment. It has been
well documented that ZP birefringence and MS
visualization could be considered for evaluation
of oocyte developmental capacity and subsequent
ART outcome (10, 11, 36). Lierman and colleagues
compared spindle presence in the vitrified and non-
vitrified IVM oocytes collected from the medulla
suspension of trans-men. They reported a non-
significant presence of bipolar spindles in both vit-
rified and non-vitrified group by over than 50% (37).
Two other studies evaluated ZP and MS among
in vivo and in vitro matured oocytes and stated
the higher percentages of high ZP birefringence
in IVM oocytes in addition to similar MS visual-
ization between groups (10, 11). Previous studies
indicated that IVM has not negatively affected ZP
birefringence (38, 39); however, our results showed
that vitrification may have a detrimental effect on
oocyte quality through alteration in ZP and MS
condition.
5. Conclusion
In conclusion, vitrification had the most detri-
mental effect on oocyte maturation and viability
as well as ZP birefringence and the presence of
MS in the oocytes. Therefore, vitrification of mature
oocytes after IVM may be more promising. Opti-
mization of the vitrification procedure in addition
to embryo cryopreservation is the most reputable
method for cancerous patients.
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